参考文献/References:
[1]Howlader N,Forjaz G,Mooradian MJ,et al.The Effect of Advances in Lung-Cancer Treatment on Population Mortality[J].New England Journal of Medicine,2020,383(7):640-649. [2]Chen W,Zheng R,Baade P,et al.Cancer statistics in China,2015[J].CA,2016,66(2):115-132. [3]Soria JC,Ohe Y,Vansteenkiste J,et al.Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J].New England Journal of Medicine,2018,378(2):113-125. [4]Girard N.Optimizing outcomes in EGFR mutation-positive NSCLC:which tyrosine kinase inhibitor and when[J].Future Oncology,2018,14(11):1117-1132. [5]Song J,Shi J,Dong D,et al.A new approach to predict progression-free survival in stage IV EGFR-mutant NSCLC patients with EGFR-TKI therapy[J].Clin Cancer Res,2018,24(15):3583-3592. [6]Giuliani J,Martelli S,Remo A,et al.Primary TKI Resistance in Advanced Non-small Cell Lung Cancer with EGFR Mutation:An Open Question[J].Tumori Journal,2015,101(4):e115-e117. [7]王蓉,郭人花,卢凯华,等.肺腺癌EGFR-TKI耐药后继续靶向药联合化疗的临床疗效[J].南京医科大学学报(自然科学版),2018,38(12):1701-1705. [8]沈凯凯,魏雨晴,汪向海,等.晚期肺腺癌患者一线使用EGFR-TKI获得性耐药后T790M与预后的相关性[J].国际病理科学与临床杂志,2018,38(11):2433-2441. [9]张郜晨茜,杨兴辉,舒琦瑾.南方红豆杉水提物抑制T790M突变及c-MET扩增导致的吉非替尼耐药体外研究[J].中国中西医结合杂志,2020,40(6):75-80. [10]Wang L,Dong X,Ren Y,et al.Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway[J].Cell Death & Disease,2018,9(2):129. [11]To KKW,Wu WKK,Loong HHF.PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy[J].European Journal of Pharmacology,2018(823):19-26. [12]Guerard M,Robin T,Perron P,et al.Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI[J].Cancer Letters,2018(420):146-155. [13]Wang X,Yin H,Zhang H,et al.NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers[J].Cell Death&Disease,2018,9(4):418-420. [14]Nan J,Du Y,Chen X,et al.TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers[J].Molecular Cancer Therapeutics,2014,13(3):617-629. [15]Zhao M,Zhang Y,Li J,et al.Histone deacetylation,as opposed to promoter methylation,results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC[J].Oncology Letters,2018,15(1):1089-1096. [16]Chen H,Wang Y,Lin C,et al.Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction[J].Oncotarget,2017,8(55):93825-93838. [17]Zhao M,Zhang Y,Cai W,et al.The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer[J].Cancer,2014,120(15):2299. [18]Kim GW,Song JS,Choi CM,et al.Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival[J]Lung Cancer,2015,88(2):139-146. [19]Wu DW,Chen CY,Chu CL,et al.Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability[J].Oncogene,2016,35(5):621-630. [20]朱凯,张爱萍,谢丽心,等.非小细胞肺癌患者外周血KRAS与EGFR基因突变并存及对一线EGFR-TKI治疗选择的相关性研究[J].海峡药学,2018,30(12):213-215. [21]刘小云,吴小延,邵琼,等.基于分子标签二代测序技术的非小细胞肺癌驱动基因变异分析[J].分子诊断与治疗杂志,2019,11(6):468-473. [22]张健.培美曲塞治疗EGFR-TKI获得性耐药晚期NSCLC的疗效观察[J].现代肿瘤医学,2018,26(22):3578-3581. [23]吕爽,李卉,巴雅力格,等.高通量基因测序技术检测外周血循环肿瘤DNA基因突变在非小细胞肺癌中的应用[J].现代肿瘤医学,2019,27(13):2291-2295. [24]Kobayashi Y,Azuma K,Nagai H,et al.Characterization of EGFR T790M,L792F,and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer[J].Molecular Cancer Therapeutics,2017,16(2):33-39. [25]Jakobsen JN,Santoni-Rugiu E,Grauslund M,et al.Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment[J].Oncotarget,2018,9(40):26195-26208. [26]Alexander M,Lin E,Cheng H.Leptomeningeal Metastases in Non-small Cell Lung Cancer:Optimal Systemic Management in NSCLC With and Without Driver Mutations[J].Current Treatment Options in Oncology,2020,21(9):72. [27]Mack PC,Banks KC,Espenschied CR,et al.Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer:Analysis of over 8000 cases[J].Cancer,2020,126(14):3219-3228. [28]Feng W,Xie Q,Liu S,et al.Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer[J].Cancer Ence,2018,109(6):1775-1786. [29]Xiao J,Wang F,Lu H,et al.Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells[J].Cell Death&Disease,2019,10(10):777. [30]顾国民,卢素琼,展翼翼,等.EGFR-TKI获得性耐药相关T790M突变与非小细胞肺癌上皮间质转化和IGF-1R的相关性研究[J].肿瘤药学,2019,9(3):380-383. [31]Yue J,Lv D,Wang C,et al.Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta 3[J].Oncogene,2018,37(31):4300-4312. [32]王永涛,李波清.IGF信号通路与肺腺癌EGFR-TKI治疗获得性耐药的关系[J].实用癌症杂志,2016,2(1):29-32. [33]Wu SG,Shih JY.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J].Molecular Cancer,2018,17(1):38. [34]Zhao H,Huang Y,Shi J,et al.ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC[J].Frontiers in Pharmacology,2018(9):1312. [35]Qiu D,Zhang Y,Xue YB,et al.Chemotherapy combined with Endostar as salvage treatment for EGFR-tyrosine kinase inhibitor primary resistance in an advanced non-small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion:A case report[J].Thoracic Cancer,2019,10(4):1023-1028. [36]Zou B,Lee V,Yan H.Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis[J].BMC Bioinformatics,2018,19(1):88-93. [37]Zeng L,Xiao L,Jiang WJ,et al.Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population[J].Lung Cancer,2020(141):82-88. [38]Kim DH,Choi YJ,Kim SY,et al.Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer[J].Targeted Oncology,2018,13(2):35-39. [39]Rossi A,La Salvia A,Di Maio M.Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer[J].Expert Review of Respiratory Medicine,2017,11(3):171-179. [40]Santos FS,Santos RJ,Leite V.Sorafenib and Sunitinib for the Treatment of Metastatic Thyroid Cancer of Follicular Origin:A 7-Year Single-Centre Experience[J].European Thyroid Journal,2019,8(5):262-267. [41]Asahi Y,Suzuki T,Sawada A,et al.Pneumatosis Cystoides Intestinalis Secondary to Sunitinib Treatment for Gastrointestinal Stromal Tumor[J].Case Reports in Gastroenterology,2018 12(2):432-438. [42]Takemoto S,Nakamura Y,Gyoutoku H,et al.Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma(NSCLC)overexpressing ERCC1 messenger RNA:Non-platinum triplet for NSCLC[J].Thoracic Cancer,2019,10(3):452-458. [43]Lohmeyer J,Nerreter T,Dotterweich J,et al.Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose and time-dependent manner[J].Clinical&Experimental Immunology,2018,193(1):64-72. [44]Azuma K,Hirashima T,Yamamoto N,et al.Phase II study of erlotinib plus tivantinib(ARQ 197)in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI,gefitinib or erlotinib[J].Esmo Open,2016,1(4):e000063. [45]Kallu J,Banerjee T,Sulthana S,et al.Nanomedicine-Assisted Combination Therapy of NSCLC:New Platinum-Based Anticancer Drug Synergizes the Therapeutic Efficacy of Ganetespib[J].Nanotheranostics,2019,3(1):120-134. [46]来森艳,曹小年,吴维,等.miR-19a通过抑制c-MET的表达逆转HCC827细胞吉非替尼耐药[J].华中科技大学学报(医学版),2019,48(2):46-49. [47]Counago F,Montemuino S,Martin M,et al.Prognostic factors in neoadjuvant treatment followed by surgery in stage ⅢA-N2 non-small cell lung cancer:a multi-institutional study by the Oncologic Group for the Study of Lung Cancer(Spanish Radiation Oncology Society)[J].Clinical and Translational Oncology,2019,21(6):735-744. [48]李山岭,王杰,陈素芳,等.CT引导下射频消融联合EGFR-TKI靶向治疗中晚期非小细胞肺癌的效果及对免疫功能的影响[J].实用临床医药杂志,2018,22(11):52-55,59.
相似文献/References:
[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,31(07):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,31(07):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的
表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,31(07):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,31(07):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,32(07):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,31(07):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,31(07):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(07):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2022,35(07):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Medical Information,2019,32(07):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]